Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis.

Vilchèze C, Hartman T, Weinrick B, Jain P, Weisbrod TR, Leung LW, Freundlich JS, Jacobs WR Jr.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4495-4500. doi: 10.1073/pnas.1704376114. Epub 2017 Apr 10.

2.

Dual-Reporter Mycobacteriophages (Φ2DRMs) Reveal Preexisting Mycobacterium tuberculosis Persistent Cells in Human Sputum.

Jain P, Weinrick BC, Kalivoda EJ, Yang H, Munsamy V, Vilcheze C, Weisbrod TR, Larsen MH, O'Donnell MR, Pym A, Jacobs WR Jr.

mBio. 2016 Oct 25;7(5). pii: e01023-16. doi: 10.1128/mBio.01023-16.

3.

Fluorescent Reporter DS6A Mycobacteriophages Reveal Unique Variations in Infectibility and Phage Production in Mycobacteria.

Mayer O, Jain P, Weisbrod TR, Biro D, Ho L, Jacobs-Sera D, Hatfull GF, Jacobs WR Jr.

J Bacteriol. 2016 Nov 4;198(23):3220-3232. Print 2016 Dec 1.

4.

Einstein Contained Aerosol Pulmonizer (ECAP): Improved Biosafety for Multi-Drug Resistant (MDR) and Extensively Drug Resistant (XDR) Mycobacterium tuberculosis Aerosol Infection Studies.

Chen B, Weisbrod TR, Hsu T, Sambandamurthy V, Vieira-Cruz D, Chibbaro A, Ghidoni D, Kile T, Barkley WE, Vilchèze C, Colon-Berezin C, Thaler DS, Larsen MH, Sturm AW, Jacobs WR Jr.

Appl Biosaf. 2011 Oct 27;16(3):134-138.

5.

Protection of Mycobacterium tuberculosis from reactive oxygen species conferred by the mel2 locus impacts persistence and dissemination.

Cirillo SL, Subbian S, Chen B, Weisbrod TR, Jacobs WR Jr, Cirillo JD.

Infect Immun. 2009 Jun;77(6):2557-67. doi: 10.1128/IAI.01481-08. Epub 2009 Apr 6.

6.

Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.

Vilchèze C, Wang F, Arai M, Hazbón MH, Colangeli R, Kremer L, Weisbrod TR, Alland D, Sacchettini JC, Jacobs WR Jr.

Nat Med. 2006 Sep;12(9):1027-9. Epub 2006 Aug 13.

PMID:
16906155
7.

Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria.

Vilchèze C, Weisbrod TR, Chen B, Kremer L, Hazbón MH, Wang F, Alland D, Sacchettini JC, Jacobs WR Jr.

Antimicrob Agents Chemother. 2005 Feb;49(2):708-20.

8.
9.

Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis.

Alland D, Kramnik I, Weisbrod TR, Otsubo L, Cerny R, Miller LP, Jacobs WR Jr, Bloom BR.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13227-32.

10.

NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis.

Miesel L, Weisbrod TR, Marcinkeviciene JA, Bittman R, Jacobs WR Jr.

J Bacteriol. 1998 May;180(9):2459-67.

11.

Genetic determination of the meso-diaminopimelate biosynthetic pathway of mycobacteria.

Cirillo JD, Weisbrod TR, Banerjee A, Bloom BR, Jacobs WR Jr.

J Bacteriol. 1997 Apr;179(8):2792. No abstract available.

12.

Cloning of the dapB gene, encoding dihydrodipicolinate reductase, from Mycobacterium tuberculosis.

Pavelka MS Jr, Weisbrod TR, Jacobs WR Jr.

J Bacteriol. 1997 Apr;179(8):2777-82.

13.

Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates.

Balasubramanian V, Pavelka MS Jr, Bardarov SS, Martin J, Weisbrod TR, McAdam RA, Bloom BR, Jacobs WR Jr.

J Bacteriol. 1996 Jan;178(1):273-9.

14.

In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis.

McAdam RA, Weisbrod TR, Martin J, Scuderi JD, Brown AM, Cirillo JD, Bloom BR, Jacobs WR Jr.

Infect Immun. 1995 Mar;63(3):1004-12.

15.
16.

Isolation and characterization of the aspartokinase and aspartate semialdehyde dehydrogenase operon from mycobacteria.

Cirillo JD, Weisbrod TR, Pascopella L, Bloom BR, Jacobs WR Jr.

Mol Microbiol. 1994 Feb;11(4):629-39.

PMID:
7910936

Supplemental Content

Loading ...
Support Center